O	0	8	Surgical
O	9	19	prevention
O	20	22	of
B-condition	23	26	arm
I-condition	27	37	lymphedema
O	38	43	after
O	44	50	breast
O	51	57	cancer
O	58	67	treatment
O	67	68	.

O	69	71	To
O	72	85	prospectively
O	86	92	assess
O	93	96	the
O	97	105	efficacy
O	106	108	of
O	109	112	the
B-intervention	113	122	lymphatic
I-intervention	123	136	microsurgical
I-intervention	137	147	preventive
I-intervention	148	155	healing
I-intervention	156	164	approach
I-intervention	165	166	(
I-intervention	166	172	LYMPHA
I-intervention	172	173	)
O	174	176	to
O	177	184	prevent
O	185	195	lymphedema
O	196	201	after
O	202	210	axillary
O	211	221	dissection
O	222	223	(
O	223	225	AD
O	225	226	)
O	227	230	for
O	231	237	breast
O	238	244	cancer
O	245	254	treatment
O	254	255	.

O	256	261	Among
B-total-participants	262	264	49
O	265	276	consecutive
O	277	282	women
O	283	291	referred
O	292	296	from
O	297	302	March
O	303	307	2008
O	308	310	to
O	311	320	September
O	321	325	2009
O	326	328	to
O	329	336	undergo
O	337	345	complete
O	346	348	AD
O	348	349	,
B-total-participants	350	352	46
O	353	357	were
O	358	366	randomly
O	367	374	divided
O	375	377	in
O	378	379	2
O	380	386	groups
O	386	387	.

B-intervention-participants	388	394	Twenty
I-intervention-participants	394	395	-
I-intervention-participants	395	400	three
O	401	410	underwent
O	411	414	the
O	415	421	LYMPHA
O	422	431	technique
O	432	435	for
O	436	439	the
O	440	450	prevention
O	451	453	of
O	454	457	arm
O	458	468	lymphedema
O	468	469	.

O	470	473	The
O	474	479	other
B-control-participants	480	482	23
O	483	491	patients
O	492	495	had
B-control	496	498	no
I-control	499	509	preventive
I-control	510	518	surgical
I-control	519	527	approach
I-control	528	529	(
I-control	529	536	control
I-control	537	542	group
I-control	542	543	)
O	543	544	.

O	545	548	The
O	549	555	LYMPHA
O	556	565	procedure
O	566	575	consisted
O	576	578	of
O	579	589	performing
O	590	599	lymphatic
O	599	600	-
O	600	606	venous
O	607	618	anastomoses
O	619	620	(
O	620	623	LVA
O	623	624	)
O	625	627	at
O	628	631	the
O	632	636	time
O	637	639	of
O	640	642	AD
O	642	643	.

O	644	647	All
O	648	656	patients
O	657	666	underwent
O	667	679	preoperative
O	680	698	lymphoscintigraphy
O	699	700	(
O	700	702	LS
O	702	703	)
O	703	704	.

O	705	713	Patients
O	714	718	were
O	719	727	followed
O	728	730	up
O	731	741	clinically
O	742	744	at
O	745	746	1
O	746	747	,
O	748	749	3
O	749	750	,
O	751	752	6
O	752	753	,
O	754	756	12
O	756	757	,
O	758	761	and
O	762	764	18
O	765	771	months
O	772	774	by
O	775	784	volumetry
O	784	785	.

O	786	801	Postoperatively
O	801	802	,
O	803	805	LS
O	806	809	was
O	810	819	performed
O	820	825	after
O	826	828	18
O	829	835	months
O	836	838	in
O	839	841	41
O	842	850	patients
O	851	852	(
B-intervention-participants	852	854	21
O	855	864	treatment
O	865	870	group
O	871	874	and
B-control-participants	875	877	20
O	878	885	control
O	886	891	group
O	891	892	)
O	892	893	.

O	894	897	Arm
O	898	904	volume
O	905	908	and
O	909	911	LS
O	912	923	alterations
O	924	928	were
O	929	937	assessed
O	937	938	.

B-outcome	939	949	Lymphedema
O	950	958	appeared
O	959	961	in
B-iv-bin-abs	962	963	1
O	964	971	patient
O	972	974	in
O	975	978	the
O	979	988	treatment
O	989	994	group
O	995	996	6
O	997	1003	months
O	1004	1009	after
O	1010	1017	surgery
O	1018	1019	(
B-iv-bin-percent	1019	1020	4
I-iv-bin-percent	1020	1021	.
I-iv-bin-percent	1021	1023	34
I-iv-bin-percent	1023	1024	%
O	1024	1025	)
O	1025	1026	.

O	1027	1029	In
O	1030	1033	the
O	1034	1041	control
O	1042	1047	group
O	1047	1048	,
B-outcome	1049	1059	lymphedema
O	1060	1068	occurred
O	1069	1071	in
B-cv-bin-abs	1072	1073	7
O	1074	1082	patients
O	1083	1084	(
B-cv-bin-percent	1084	1086	30
I-cv-bin-percent	1086	1087	.
I-cv-bin-percent	1087	1089	43
I-cv-bin-percent	1089	1090	%
O	1090	1091	)
O	1091	1092	.

O	1093	1095	No
O	1096	1109	statistically
O	1110	1121	significant
O	1122	1133	differences
O	1134	1136	in
O	1137	1140	the
B-outcome	1141	1144	arm
I-outcome	1145	1151	volume
O	1152	1156	were
O	1157	1165	observed
O	1166	1168	in
O	1169	1172	the
O	1173	1182	treatment
O	1183	1188	group
O	1189	1195	during
O	1196	1202	follow
O	1202	1203	-
O	1203	1205	up
O	1205	1206	,
O	1207	1212	while
O	1213	1216	the
O	1217	1220	arm
O	1221	1227	volume
O	1228	1230	in
O	1231	1234	the
O	1235	1242	control
O	1243	1248	group
O	1249	1255	showed
O	1256	1257	a
O	1258	1269	significant
O	1270	1278	increase
O	1279	1284	after
O	1285	1286	1
O	1286	1287	,
O	1288	1289	3
O	1289	1290	,
O	1291	1294	and
O	1295	1296	6
O	1297	1303	months
O	1304	1308	from
O	1309	1318	operation
O	1318	1319	.

O	1320	1325	There
O	1326	1329	was
O	1330	1341	significant
O	1342	1352	difference
O	1353	1360	between
O	1361	1364	the
O	1365	1366	2
O	1367	1373	groups
O	1374	1376	in
O	1377	1380	the
B-outcome	1381	1387	volume
I-outcome	1388	1395	changes
O	1396	1400	with
O	1401	1408	respect
O	1409	1411	to
O	1412	1420	baseline
O	1421	1426	after
O	1427	1428	1
O	1428	1429	,
O	1430	1431	3
O	1431	1432	,
O	1433	1434	6
O	1434	1435	,
O	1436	1438	12
O	1438	1439	,
O	1440	1443	and
O	1444	1446	18
O	1447	1453	months
O	1454	1459	after
O	1460	1467	surgery
O	1468	1469	(
O	1469	1474	every
O	1475	1481	timing
O	1482	1483	P
O	1484	1489	value
O	1490	1491	<
O	1492	1493	0
O	1493	1494	.
O	1494	1496	01
O	1496	1497	)
O	1497	1498	.

O	1499	1505	LYMPHA
O	1506	1516	represents
O	1517	1518	a
O	1519	1524	valid
O	1525	1534	technique
O	1535	1538	for
O	1539	1546	primary
O	1547	1557	prevention
O	1558	1560	of
O	1561	1570	secondary
O	1571	1574	arm
O	1575	1585	lymphedema
O	1586	1590	with
O	1591	1593	no
O	1594	1598	risk
O	1599	1601	of
O	1602	1609	leaving
O	1610	1620	undetected
O	1621	1630	malignant
O	1631	1638	disease
O	1639	1641	in
O	1642	1645	the
O	1646	1652	axilla
O	1652	1653	.
